Pfizer Reports Encouraging Mid-Stage Results for Experimental Eczema Drug

Pfizer announced encouraging mid-stage results for its experimental eczema treatment, tilrekimig. Phase 2 data showed significant skin clearance in adults with moderate-to-severe atopic dermatitis.